Based on this, the aim of our study was to evaluate whether modulating ET1 bioavailability through ECE1 inhibition or the administration of recombinant NEP (rNEP) could reduce aggressive traits in gallbladder cancer cells, including EMT, stemness, migration, invasion, and tumorigenic potential. The gene discussed is EDN1; the disease is gallbladder cancer.